Organ Regeneration Deep Dive: Autologous Stem Cell Activation Therapy Enables In-Vivo Liver Self-Repair

At the end of March 2028, a team from Osaka University's Institute for Regenerative Medicine published a paper in The Lancet reporting breakthrough results from their "in-situ organ regeneration" technology in primate experiments. The technology activates dormant endogenous stem cells within organs by locally injecting a combination of signaling molecules called RegenSignal-3, which differentiate into functional hepatocytes and rebuild damaged tissue.

In rhesus macaque experiments, the research team surgically removed 70% of the liver, then injected RegenSignal-3 at the resection surface. After 14 days, MRI imaging showed liver volume had recovered to 92% of pre-surgical levels, with liver function markers (ALT, AST, bilirubin) all returning to normal ranges. The control group (injected with saline only) recovered to 58% of pre-surgical liver volume in the same period.

RegenSignal-3 consists of three signaling molecules: Wnt3a (promoting stem cell proliferation), HGF (inducing hepatocyte differentiation), and a novel peptide called StemWake (lifting stem cells from dormancy). The ratio and release timing of the three are precisely controlled to mimic the natural liver formation process during embryonic development. Paper corresponding author Professor Hiroaki Nakata stated that previous regenerative medicine mainly relied on culturing stem cells outside the body and re-implanting them, while RegenSignal-3's advantage is completing the entire regeneration process in vivo without external manipulation.

Japan's PMDA has approved RegenSignal-3 for Phase I human clinical trials, planning to recruit 30 patients with late-stage liver cirrhosis. However, the University of Tokyo's medical ethics committee raised safety concerns — if signaling molecules diffuse to non-target areas, they could trigger abnormal cell proliferation in non-target organs. The research team responded that RegenSignal-3's molecular design includes a "decay domain" that automatically degrades within 48 hours after injection, leaving no long-term residue in the body.

Globally, approximately 30,000 people await liver transplants annually, with about one-third dying before finding a suitable donor. If in-situ regeneration technology proves effective in human trials, it could fundamentally change the treatment paradigm for end-stage liver disease.